Recently, Sansure Biotech Inc(688289) in response to investors’ questions on the interactive easy platform, said that covid-19 antigen detection products that can be used for home self-test have applied for EU CE certification and US FDA certification, which will further provide diversified identification and detection schemes for the prevention and control of international epidemics and improve the comprehensive competitiveness of the company’s products.
In March 12th, the official account of Sansure Biotech Inc(688289) said that since March 12th, 7 New Coronavirus Sansure Biotech Inc(688289) (SARS-CoV-2) antigen detection kits, including professional laboratory versions and home self testing versions, have been distributed worldwide in Germany, France, Britain, Italy, Portugal and Greece. Nearly 40 countries and regions, including Austria, have obtained registration certification and entered the white list of local government procurement, which has been widely used, providing important help for local government epidemic management and residents’ self-test.
According to the introduction, two independent New Coronavirus Sansure Biotech Inc(688289) detection kit developed by the company can be applied to the epidemic prevention and control and individual home self testing. The kit contains sampling tools, lysate and detection devices, and does not need other testing equipment. Through the collection of patients’ nasopharyngeal swab or oropharyngeal swab samples for detection, the operation is simple and sensitive. The results can be obtained in only 10-15 minutes, which can help patients quickly and accurately evaluate the infection of new coronavirus.
In fact, nucleic acid testing has always been the “gold standard” for New Coronavirus detection. In recent years, Sansure Biotech Inc(688289) has built a comprehensive control system for New Coronavirus, which includes nucleic acid detection and antigen detection.
Sansure Biotech Inc(688289) 3 on March 11, it was said on the investor interaction platform that the company’s covid-19 nucleic acid detection reagent would not miss the detection and miss the target of the mutant Omicron (BA. 2). In the follow-up, the company will continue to closely track the latest developments of covid-19 virus variants around the world, monitor the specificity, accuracy and sensitivity of products, and continue to contribute to epidemic prevention and control.
According to the disclosure, in 2021, Sansure Biotech Inc(688289) covid-19 nucleic acid detection reagent delivered 219897700 people, an increase of 134.66% over the same period of the previous year; In the whole year, 10696 instruments were delivered, an increase of 74.71% over the same period of last year.
